Table 2 Prevalence (95% confidence interval, CI) of type 2 diabetes (T2D), screen-detected type 2 diabetes (ST2D), total type 2 diabetes (TT2D), impaired glucose tolerance (IGT), impaired fasting glucose (IFG), abnormal glucose tolerance (AGT= TT2D, IGT, or IFG) in the study sample according to sex and age groups.
MEN | WOMEN | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
45–54 | 55–64 | 65–74 | Total | p* | 45–54 | 55–64 | 65–74 | Total | p* | |
n | 405 | 485 | 474 | 1364 | 479 | 511 | 471 | 1461 | ||
T2D, % | 2.7 | 8.2 | 12.2 | 7.1 | < 0.001 | 2.3 | 3.5 | 8.3 | 3.9 | < 0.001 |
(95% CI) | (1.4–4.8) | (6.0–11.1) | (9.4–15.5) | (5.7–8.5) | (1.2–4.1) | (2.1–5.5) | (6.0–11.1) | (2.9–4.9) | ||
ST2D, % | 5.9 | 8.7 | 12.7 | 9.3 | 0.002 | 2.5 | 8.0 | 12.1 | 7.3 | < 0.001 |
(95% CI) | (3.8–8.7) | (6.3–11.5) | (9.8–16.0) | (7.7–11.0) | (1.3–4.3) | (5.8–10.7) | (9.3–15.4) | (5.9–8.7) | ||
TT2D, % | 8.6 | 16.9 | 24.9 | 16.4 | < 0.001 | 4.8 | 11.5 | 20.4 | 11.2 | < 0.001 |
(95% CI) | (6.1–11.8) | (13.7–20.5) | (21.1–29.0) | (14.3–18.5) | (3.1–7.1) | (8.9–14.6) | (16.8–24.3) | (9.6–12.8) | ||
IGT, % | 7.9 | 15.1 | 23.8 | 15.5 | < 0.001 | 10.4 | 15.1 | 25.1 | 17.0 | < 0.001 |
(95% CI) | (5.5–11.0) | (12.0–18.5) | (20.1–27.9) | (13.5–17.6) | (7.8–13.5) | (12.1–18.5) | (21.2–29.2) | (15.0–19.1) | ||
IFG, % | 9.9 | 12.4 | 5.9 | 10.0 | 0.002 | 5.2 | 5.1 | 4.2 | 5.2 | 0.746 |
(95% CI) | (7.2–13.2) | (9.6–15.6) | (4.0–8.4) | (8.2–11.8) | (3.4–7.6) | (3.4–7.4) | (2.6–6.5) | (3.9–6.5) | ||
AGT, % | 26.4 | 44.3 | 54.6 | 42.0 | < 0.001 | 20.5 | 31.7 | 49.7 | 33.4 | < 0.001 |
(95% CI) | (22.2–31.0) | (39.9–48.9) | (50.0–59.2) | (39.2–44.8) | (16.9–24.4) | (27.7–35.9) | (45.1–54.3) | (30.9–36.0) | ||